Results 101 to 110 of about 26,095 (135)

Trousseau syndrome presenting with recurrent multi-territory infarctions: a case report of two patients highlighting divergent outcomes and dynamic hypercoagulability under direct oral anticoagulants and low-molecular-weight heparin. [PDF]

Front Cardiovasc Med
Ding G, Xu J, Yao M.
europepmc   +1 more source

Enhancement of the Solubility and Dissolution Profile of Rivaroxaban by the Antisolvent Precipitation Technique: A Promising Approach. [PDF]

Polymers (Basel)
Benga CM, Ozon EA, Musuc AM, Anuța V, Sârbu I, Surdu VA, Teodorescu F, Rusu A, Popa L, Ghica MV, Chandak A, Pîrvu CED.   +11 more
europepmc   +1 more source

The influence of ABCB1 rs4148738 (C>T) polymorphism on rivaroxaban exposure and bleeding risk in Iraqi patients with non-valvular atrial fibrillation. [PDF]

Qatar Med J
Jalel HK, Hamid MO, Ibadi MH.
europepmc   +1 more source

Pharmaceutical Co-Crystal Formulation of Rivaroxaban with Niacinamide: Preparation, Characterization, and In Vitro Release Evaluation. [PDF]

Materials (Basel)
Solomon C, Sarbu I, Anuța V, Ozon EA, Musuc AM, Rusu A, Surdu VA, Chandak A, Gavriloaia RM, Fița AC, Nită DT, Mitu MA.   +11 more
europepmc   +1 more source

Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone-dependent Cushing syndrome.

J Clin Endocrinol Metab
Htut Z, Mundhra A, Lazarus K, Martin N, Papadopoulou D, Meeran K, Wernig F.   +6 more
europepmc   +1 more source

Direct oral anticoagulants versus warfarin for left ventricular thrombus: an updated systematic review and meta-analysis of randomized and observational studies. [PDF]

Front Cardiovasc Med
Alfehaid L, Alhuwayshil J, Almousa S, Habeeb E, Al Yami MS.   +4 more
europepmc   +1 more source

Methodological Concerns Regarding a Recent Meta-Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation. [PDF]

Clin Cardiol
Samir OK, Datta N.
europepmc   +1 more source

Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety. [PDF]

Front Pharmacol
Alqahtani S, Almutairi A, Aldajani F, Basudan M, Alzahrani A, Alenazi M, Alsarhani E, Alsubaie A, Almaghrabi A, Bamehriz F, Alsubaie H, Algahtani F.   +11 more
europepmc   +1 more source

Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants. [PDF]

Front Pharmacol
Terrier J, Gosselin P, Combescure C, Fontana P, Daali Y, Reny JL.   +5 more
europepmc   +1 more source